ViiV Healthcare is looking to investigate twice-yearly dosing of its human immunodeficiency virus (HIV) therapy which has been able to suppress viral load in patients dosed every four months in a ...

Biktarvy’s main competitor in that market is Juluca, which ViiV Healthcare launched in June 2018. The early signs are that physicians in Germany are significantly more inclined to prescribe ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...

Created by ViiV Healthcare — a specialist pharmaceutical company dedicated to HIV medicines and research that is majority-owned by GSK — the production acknowledges the stresses and micro ...

ViiV is also working with Janssen to develop a once-monthly injectable HIV combo regimen, which recently reported positive phase 3 trial results. George Underwood 9 April, 2019 ...